F

Fennec Pharmaceuticals Inc
TSX:FRX

Watchlist Manager
Fennec Pharmaceuticals Inc
TSX:FRX
Watchlist
Price: 10.63 CAD 2.31%
Market Cap: 290.4m CAD

Relative Value

The Relative Value of one FRX stock under the Base Case scenario is 24.62 CAD. Compared to the current market price of 10.63 CAD, Fennec Pharmaceuticals Inc is Undervalued by 57%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FRX Relative Value
Base Case
24.62 CAD
Undervaluation 57%
Relative Value
Price
F
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
57
vs Industry
67
Median 3Y
8.2
Median 5Y
8.2
Industry
7.8
Forward
5.9
vs History
vs Industry
3
Median 3Y
-14.6
Median 5Y
-13.7
Industry
24.1
Forward
-50.3
vs History
vs Industry
14
Median 3Y
-13.7
Median 5Y
-14.9
Industry
21.8
vs History
vs Industry
12
Median 3Y
-9.5
Median 5Y
-13.6
Industry
23.8
vs History
vs Industry
1
Median 3Y
-36.8
Median 5Y
-28.1
Industry
3.3
vs History
55
vs Industry
58
Median 3Y
8.1
Median 5Y
8.1
Industry
8
Forward
5.8
vs History
38
vs Industry
61
Median 3Y
9
Median 5Y
4.3
Industry
10.3
vs History
vs Industry
2
Median 3Y
-13.9
Median 5Y
-12.6
Industry
6.3
Forward
45.3
vs History
vs Industry
2
Median 3Y
-13.9
Median 5Y
-12.6
Industry
6.7
Forward
-92.9
vs History
vs Industry
14
Median 3Y
-14.1
Median 5Y
-14.1
Industry
7.9
vs History
vs Industry
11
Median 3Y
-14.1
Median 5Y
-14.1
Industry
6.3
vs History
63
vs Industry
18
Median 3Y
15.1
Median 5Y
13.8
Industry
5.5

Multiples Across Competitors

FRX Competitors Multiples
Fennec Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fennec Pharmaceuticals Inc
TSX:FRX
262.6m CAD 6.8 -37.8 -55.5 -55.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 710 712 -160 222 -194 560.6 -192 340.5
US
Abbvie Inc
NYSE:ABBV
406.2B USD 6.8 173.2 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
178.9B USD 5 25.5 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
157.2B USD 5.4 19.5 13.1 13.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.9B USD 10 31.8 23.3 24.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 089.8 -533.3 -580.7 -565.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83B USD 5.8 18.2 17.3 19.6
AU
CSL Ltd
ASX:CSL
85.1B AUD 3.6 18.9 12.7 15.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.5B USD 16.7 1 228.8 161.5 195.9
NL
argenx SE
XBRU:ARGX
44.5B EUR 14.5 34.1 58.9 60.5
P/E Multiple
Earnings Growth PEG
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average P/E: 193.7
Negative Multiple: -37.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 222 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 228.8
N/A N/A
NL
argenx SE
XBRU:ARGX
34.1
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average EV/EBITDA: 40.2
Negative Multiple: -55.5
169%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.9
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
F
Fennec Pharmaceuticals Inc
TSX:FRX
Average EV/EBIT: 46.4
Negative Multiple: -55.5
136%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 340.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.1
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.6
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.9
N/A N/A
NL
argenx SE
XBRU:ARGX
60.5
N/A N/A